NervGen Pharma Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGENF research report →
Companywww.nervgen.com
NervGen Pharma Corp. , together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease.
- CEO
- Adam H. Rogers
- IPO
- 2019
- Employees
- 11
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $312.89M
- P/E
- -8.54
- P/S
- 0.00
- P/B
- 108.37
- EV/EBITDA
- -15.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -17536.81%
- ROIC
- -719.57%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-24,005,895 · -7.25%
- EPS
- $-0.36 · 5.26%
- Op Income
- $-24,931,994
- FCF YoY
- -47.25%
Performance & Tape
- 52W High
- $6.30
- 52W Low
- $1.50
- 50D MA
- $4.41
- 200D MA
- $3.11
- Beta
- 0.76
- Avg Volume
- 157.91K
Get TickerSpark's AI analysis on NGENF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NGENF Coverage
We haven't published any research on NGENF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NGENF Report →